Tivic Health Systems, Inc. Overview
Pro stress-test →Tivic Health Systems is a diversified therapeutics company that harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. The company's lead drug candidate, Entolimod™ to treat Acute Radiation Syndrome (ARS), is in late-stage development.
Strategic Profile
Pro stress-test →Tivic has evolved into a diversified immunotherapeutics and health technology company. In January 2026, the company presented Entolimod at a BARDA TechWatch meeting with U.S. defense and health agencies, showcasing clinical results and manufacturing readiness, with BARDA requesting expedited follow-up to discuss potential inclusion in the Strategic National Stockpile.
Competitive Landscape
Pro stress-test →Entolimod is a TLR5 agonist in late-stage development for Acute Radiation Syndrome, competing in the niche radiation countermeasure market. Key competitors include established biotech firms and government-funded radiation response programs. The company's legacy ClearUP consumer product operates in the OTC sinus relief market against traditional and electrical devices.
Industry Context
Tivic Health Systems, Inc. operates in Immunotherapeutics / Bioelectronic Medicine / Contract Manufacturing.
Key facts
Founded: 2016 · Headquarters: Fremont, CA · Market cap: $2.16M